• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Government Intervention in Drug Pricing

Video

Scott Gottlieb, MD, and Ted Okon, MBA, discuss controversies surrounding a proposed legislative amendment that would allow the government to negotiate drug prices with pharmaceutical companies.

Government intervention in drug pricing would impede fair market competition, remarks Mr Okon. Dr Gottlieb and Mr Okon further discuss how the government’s control of drug pricing may affect innovation. Together, they conclude that pricing controls may affect pharmaceutical companies’ decision making regarding drug contracting and pricing. As an example, Dr Gottlieb highlights the effects of the Medicaid “best price” system.

Dr Gottlieb explains the importance of a fair market and competitive pricing scheme and their effects on insurance companies, pharmacy benefit managers, and other stakeholders in healthcare, and suggests that these are potential market-based answers to the question of how to make healthcare more affordable.


Related Videos
Dr Chun Chao
3 experts are featured in this series.
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
2 experts in this video
Dr Chun Chao
Screenshot of an interview with Shaun McKenzie, MD
1 expert is featured in this series.
Dr Chun Chao
Dr Andrew S. Oseran
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.